Hybird
DTRF Int’l Research Workshop
In order to attend the Research Workshop, you need to register for the DTRF Together We Will Weekend. In-person and virtual registration is available for the Workshop.
In-person attendees are encouraged to attend the Annual Patient Meeting on Saturday, Sept. 13th to connect with desmoid tumor patients and caregivers.
Scroll down to view a list of this year’s distinguished presenters. The complete list of presenters will be available in the coming weeks.
Designed for researchers and medical professionals, the annual DTRF International Desmoid Tumor Research Workshop is a critically important, collaborative event bringing together some of the brightest minds in the field of desmoid tumors from a variety of disciplines. It presents the latest information on desmoid treatments and research, and facilitates new collaborations to move the science forward. The Workshop also helps us identify research priorities for the coming years. We are sincerely grateful to our attendees who play a key role in advancing the field.
The DTRF International Research Workshop features:
- Scientific talks on current research and treatment
- A forum to share research findings, develop new collaborations, bring new scientists into the desmoid tumor research field, and discuss innovations that will lead to new treatments
- Live questions/answers and discussions related to the scientific talks
- Group discussions focusing on gaps in desmoid tumor science and how best to address them through high impact collaborative research
The DTRF International Research Workshop is part of the DTRF Together We Will Weekend. In order to attend the Workshop, you need to register for the Weekend.
Our 2025 Distinguished Presenters and Topics (More to follow)
"Analysis of Changes in T2-Weighted Signal Intensity and Tumor Volume and Exposure-Response in the Ringside Phase 2 Study of Varegacestat in Patients with Desmoid Tumors"
Mrinal Gounder, MD
Associate Attending Professor
Memorial Sloan Kettering
"Multiomic Profiling Uncovers Integral Immune Molecules that Drive the Pathogenic Fibroblast Milieu in Desmoid Tumors"
Cristabelle De Souza, PhD
Instructor
Stanford University School of Medicine
“Disease Burden in Desmoid Tumor Patients"
Peter Hohenberger, MD, PhD
Professor of Surgical Oncology
Mannheim University Medical Center, University of Heidelberg
"Real-World Data from a Single Institution on Nirogacestat for Refractory, Symptomatic Desmoid Tumor: Dosing, Adverse Event Management and Symptom Improvement from Medical Record Review"
Andrea Penrose
Research Assistant
Northwestern Medicine
"Genomic, Epigenomic and Transcriptomic Inter- and Intra-tumor Heterogeneity in Desmoid Tumors"
Joanna Przybyl, PhD
Assistant Professor
McGill University, Canada
"To See the Early Effect of Sorafenib on Cognition, Cardiovascular and Reproductive Functions in Patients with Fibromatosis"
Sameer Rastogi, MD
Additional Professor, Medical Oncology
Medical All India Institute of Medical Sciences, India
"Efficacy of Nirogacestat in Patients With Desmoid Tumors and Presence or Absence of Poor Prognostic Factors: Post Hoc Analyses of the Phase 3 DeFi Trial"
"The Association of Pain With Function for Adult Patients With Desmoid Tumor: Findings From the Desmoid Tumor Research Foundation Natural History Study"
Kelly Mercier, PhD
Registry Principal Investigator, DTRF Patient Registry & Natural History Study
Desmoid Tumor Research Foundation
"Concurrent genotyping and transcriptomics of Desmoid Tumor single cells and nuclei to study disease trajectory and therapeutic vulnerability: Planning Project Update"
Mushriq Al-Jazrawe, PhD
Scientific Director, High Throughput Sciences
Koch Institute for Integrative Cancer Research at MIT
